AbCelex Technologies develops single domain therapeutic antibodies for the treatment of unmet diseases. AbCelex’s proprietary technologies are based on its camelid antibody platform. Camelid antibodies are naturally a fraction of the size of typical antibodies and have properties that lend themselves to bispecific and multispecific applications, including several routes of administration allowing oral, topical and infusion delivery. AbCelex’s therapies have been validated in multiple animal species through oral administration.
Our new website will be launched soon.